AVENTIS PHARMA LIMITED

PaymentCheck Score 2025
57Fair
28.7vs last year
#3251 in UK
#34 in Life Sciences And Medical Technology
#532 in South East

Company Information

Company Number
01535640
Registered Address
410 Thames Valley Park Drive, Reading, Berkshire, England, RG6 1PT
Status
Active
Employee Count
693
Turnover
£417,800,000
EBITDA
£1,160,000

Additional Details

Company Type
Private limited Company
Incorporated On
18 December 1980
Nature of Business
46460 - Wholesale of pharmaceutical goods
Industries
Life Sciences And Medical Technology
Region
South East

Time to Pay

Average Time to Pay
50 days
Shortest Period:0 days
Longest Period:90 days
Max Contractual:90 days

Payment Timeline

Within 30 Days
41%
31-60 Days
16%
After 60 Days
43%
Not Paid Within Terms8%

Payment Features

Participates in Codes✗ No
E-Invoicing✗ No
Supply Chain Finance✗ No

Payment Score History

Excellent (80+) Good (60-79) Fair (40-59) Poor (20-39) Very Poor (<20)

Performance Reports History

Reporting Period Filed: 2025-08-05
Reporting PeriodFiling DateAverage Time to Pay (days)Paid within 30 daysPaid 31-60 daysPaid after 60 daysNot Paid within Terms
01 Jan 2025 - 30 Jun 202505 Aug 20255041%16%43%8%
31 Dec 2023 - 29 Jun 202429 Jul 20247514%18%68%35%
30 Jun 2023 - 30 Dec 202331 Jan 20247514%18%68%66%
31 Dec 2021 - 29 Jun 202229 Jul 20226023%32%45%33%
30 Jun 2021 - 30 Dec 202131 Jan 20226419%45%36%26%
30 Jun 2020 - 30 Dec 202018 Jan 20216615%43%42%30%
31 Dec 2018 - 29 Jun 201925 Jul 20194827%58%15%29%
30 Jun 2018 - 30 Dec 201824 Jan 20194538%50%12%29%

Payment Time Trends

Payment Distribution Trends

Invoice Payment Practices

This information is as reported by the business, and responses are in their own words.

Payment Terms

Standard payment terms

Standard payment terms are 90 days from the date of receipt of a valid and correct invoice

Were there any changes to the standard payment terms in the reporting period?

No information available

Any other information about payment terms

No additional information

Maximum contractual payment period agreed

90

Dispute Resolution Process

In the first instance disputes will be received by our S2P contact centre at the defined email address or telephone number printed on every Purchase Order. Queries will then be forwarded to the requester of the services/goods for information and evaluation. Failure to meet resolution will be escalated to the S2P Business Partner and include the specific Buyer for the service/goods that is responsible for the vendor relationship.

Other Payment Information

Has this business signed up to a code of conduct or standards on payment practices?

For example, signatories to The Prompt Payment Code must commit to paying 95% of their invoices within 60 days.

Does this business offer e-invoicing in relation to qualifying contracts?

This is where suppliers can electronically submit and track invoices. It's not just allowing suppliers to email them an invoice.

Does this business offer supply chain finance?

This is where a supplier who has submitted an invoice can be paid by a third-party finance provider earlier than the agreed payment date. The business would then pay the finance provider the invoiced sum.

Under its payment practices and policies, can this business deduct sums from payments under qualifying contracts as a charge for remaining on a supplier list?

During the reporting period, did the business deduct sums from payments as a charge for remaining on a supplier list?

No information available

Company Summary

AVENTIS PHARMA LIMITED is a global pharmaceutical company that focuses on developing and manufacturing innovative medicines and healthcare solutions. The company was founded in 1999 and is headquartered in Paris, France. AVENTIS PHARMA LIMITED is a subsidiary of Sanofi, a multinational pharmaceutical company.

The company's sustainability program is integrated into its business strategy, with a focus on environmental, social, and economic responsibility. AVENTIS PHARMA LIMITED is committed to reducing its carbon footprint and implementing sustainable practices in its operations. It also has a strong focus on promoting diversity and inclusion within its workforce.

AVENTIS PHARMA LIMITED offers a wide range of products and services in various therapeutic areas, including cardiovascular, diabetes, oncology, and rare diseases. Its portfolio includes both prescription and over-the-counter medicines, as well as vaccines and consumer healthcare products.

The key people at AVENTIS PHARMA LIMITED include its CEO, Olivier Brandicourt, and its Chairman of the Board of Directors, Serge Weinberg. The company has a team of over 100,000 employees worldwide who work towards its mission of improving healthcare and making a positive impact on people's lives.

For more information on AVENTIS PHARMA LIMITED, including its products and services, investors, and sustainability efforts, please visit their website at www.aventispharma.com. The company's registered office address is 174 Avenue de France, 75013 Paris, France.

Financial Metrics

Cash
£98,000
Net Worth
£1,450,567,000
Total Current Assets
£1,454,250,000
Total Current Liabilities
£504,792,000

Company Location